Log In
BCIQ
Print this Print this
 

blosozumab (LY2541546)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHumanized mAb against sclerostin
Molecular Target Sclerostin
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationOsteoporosis
Indication DetailsTreat osteoporosis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today